Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cardiothorac Vasc Anesth. 2002 Dec;16(6):695-702.

Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery.

Author information

  • 1Department of Anesthesiology and Critical Care, Duke University Medical Center, Durham, NC 27710, USA. hill0012@mc.duke.edu

Abstract

OBJECTIVE:

To evaluate the safety and preliminary efficacy of escalating doses of hemoglobin raffimer (Hemolink) with intraoperative autologous blood donation for coronary artery bypass graft (CABG) surgery.

DESIGN:

Randomized, controlled, single-blind phase II dose escalation trial.

SETTING:

Multi-institutional university setting.

PARTICIPANTS:

Adult patients (n = 60) undergoing elective CABG surgery.

INTERVENTIONS:

After induction of anesthesia, autologous whole blood was collected to achieve a hemoglobin of 7 g/dL on cardiopulmonary bypass. Patients were randomized to receive either hemoglobin raffimer (treatment) or 6% hetastarch (control) in sequential escalating dose blocks of 250 mL, 500 mL, or 750 mL. After return of autologous blood, allogeneic red blood cells were transfused according to predetermined hemoglobin triggers.

MEASUREMENTS AND MAIN RESULTS:

Safety parameters (vital signs, hematology, blood chemistry, coagulation, and adverse events) were monitored from randomization through week 4 postdischarge. Serious adverse events were distributed evenly between the 2 groups of patients. Elevated blood pressure was more frequent in the treatment group (16/28 mmHg v 9/32 mmHg, p = 0.036). In the group of 40 patients in the 750-mL dose block, 8 of the 18 treatment patients and 4 of the 22 control patients avoided allogeneic red blood cell transfusion (p = 0.093). Median volume of allogeneic red blood cells transfused was lower in treated subjects compared with controls (p = 0.042).

CONCLUSION:

Hemoglobin raffimer is well tolerated and may be effective in reducing transfusion for patients undergoing CABG surgery. Although perioperative hypertension was more frequent in the treated patients, blood pressure management prevented serious adverse sequelae. Definitive evaluation of efficacy in a larger phase III trial is warranted.

Copyright 2002, Elsevier Science (USA). All rights reserved.

PMID:
12486649
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk